Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Drug: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)Drug: SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 138
- Registration Number
- NCT06440746
- Locations
- 🇷🇺
Regional Clinical Hospital Regional state budgetary healthcare institution, Barnaul, Russian Federation
🇷🇺Ural research Institute of Phthisiopulmonology, Ekaterinburg, Russian Federation
🇷🇺State budgetary healthcare institution of the Leningrad region "Gatchina Clinical Interdistrict Hospital", Gatchina, Russian Federation
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
- Conditions
- Idiopathic Recurrent Pericarditis
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05673902
- Locations
- 🇷🇺
National medical research center named after V. A. Almazov, Saint Petersburg, Russian Federation
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
- Conditions
- Adult-Onset Still's DiseaseAOSD
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm International, LLC
- Registration Number
- NCT05432960
- Locations
- 🇷🇺
Research Institute of Rheumatology. V.A. Nasonova, Moscow, Russian Federation
🇷🇺Clinic of Nephrology, Internal and Occupational Diseases. EAT. Tareeva, University Clinical Hospital No. 3, Moscow, Russian Federation
🇷🇺State Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology, St. Petersburg, Russian Federation
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05190991
- Locations
- 🇦🇲
Center of Medical Genetics and Primary Health Care LLC, Yerevan, Armenia
🇷🇺FSBEI HE First Moscow State Medical University named after I.M. Sechenov, Moscow, Russian Federation
🇷🇺Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin, Moscow, Russian Federation
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
- Conditions
- Familial Mediterranean FeverFMF
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT05092776
- Locations
- 🇷🇺
Multidisciplinary Scientific and Clinical Center named after S.P. Botkin, Moscow, Russian Federation
🇷🇺Saint-Petersburg Pasteur Institute, Saint-Petersburg, Russian Federation
🇷🇺Terafarm, Llc, Stavropol, Russian Federation
- Prev
- 1
- 2
- 3
- Next